Ameritas Investment Partners
TRDA icon

Ameritas Investment Partners’s Entrada Therapeutics TRDA Stock Holding History

Ameritas Investment Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8K Hold
2,417
– – ﹤0.01% 2815
2026
Q1 		$30.5K Hold
2,417
– – ﹤0.01% 2375
2025
Q4 		$24.8K Hold
2,417
– – ﹤0.01% 2529
2025
Q3 		$14K Hold
2,417
– – ﹤0.01% 2836
2025
Q2 		$16.2K Hold
2,417
– – ﹤0.01% 2748
2025
Q1 		$21.9K Hold
2,417
– – ﹤0.01% 2514
2024
Q4 		$41.8K Hold
2,417
– – ﹤0.01% 2291
2024
Q3 		$38.6K Buy
2,417
+650
+37% +$10.2K ﹤0.01% 2341
2024
Q2 		$25.2K Hold
1,767
– – ﹤0.01% 2517
2024
Q1 		$25K Hold
1,767
– – ﹤0.01% 2473
2023
Q4 		$26.7K Hold
1,767
– – ﹤0.01% 2456
2023
Q3 		$27.9K Hold
1,767
– – ﹤0.01% 2388
2023
Q2 		$26.8K Buy
+1,767
New +$24.3K ﹤0.01% 2407
2022
Q2 		– Sell
-708
Closed -$7K – 3233
2022
Q1 		$7K Hold
708
– – ﹤0.01% 2901
2021
Q4 		$12K Buy
+708
New +$17.2K ﹤0.01% 2847

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Ameritas Investment Partners's TRDA Position: Q2 2026 in Review

Ameritas Investment Partners held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 2,417 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2815.

Ameritas Investment Partners first reported a position in TRDA in Q4 2021 and has held it in 15 quarters since. The position peaked at $41.8K in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Ameritas Investment Partners held 2,417 shares of Entrada Therapeutics worth $17.8K as of Q2 2026.
  • Ameritas Investment Partners left its Entrada Therapeutics share count unchanged in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2815 holding.
  • Ameritas Investment Partners first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Ameritas Investment Partners's Entrada Therapeutics position peaked at $41.8K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.